Update on Recently Approved Treatments for Hepatitis C
- First Online:
- 251 Downloads
Chronic hepatitis C virus (HCV) infection affects millions of individuals and is a significant cause of chronic liver disease and cirrhosis. Early treatment regimens relied on an immune-mediated response caused by interferon and only recently have medications acting directly on viral structures been discovered. In December 2013, two new medications, sofosbuvir and simeprevir, were approved by the US Food and Drug Administration (FDA) for treatment of chronic hepatitis C. This article reviews the approved treatment protocols for these two new medications and the clinical trials that fueled their development.
KeywordsHepatitis C treatment Sofosbuvir Simeprevir
US Food and Drug Administration
Hepatitis C virus
Sustained virologic response
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 7.Manns MP, Markova AA, Serrano BC, Cornberg M. Phase III results of boceprevir in treatment naive patients with chronic hepatitis C genotype 1. Liver Int. 2012;32 Suppl 1:29–31.Google Scholar
- 12.Buti M, Agarwal K, Horsmans Y et al. Telaprevir twice daily is noninferior to telaprevir every 8 hrs for patients with chronic hepatitis C. Gastroenterology. 2014;1–10.Google Scholar
- 13.Flamm S, Chopra S. Mechanism of action and efficacy of ribavirin for the treatment of chronic hepatitis C virus infection. UpToDate; 2013 [updated Jan 23, 2013; cited Nov 25, 2013]. Available from: http://www.uptodate.com/contents/mechanism-of-action-and-efficacy-of-ribavirin-for-the-treatment-of-chronic-hepatitis-c-virus-infection?source=search_result&search=ribavirin&selectedTitle=5%7E150. Accessed 25 Nov 2013.
- 16.www.fda.gov [homepage on the Internet]. Approval of Sovaldi (sofosbuvir) tablets for the treatment of chronic hepatitis C for consumers. US Food and Drug Administration; 2013 [updated 12/07/13, cited 12/25/13]. Available from: http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/ucm377920.htm. Accessed 25 Dec 2013.
- 17.•Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–87. This article includes all of the results from NEUTRINO and FISSION, the two phase III trials that together investigated response to SOF treatment regimens in treatment-naive patients with all six HCV genotypes.PubMedCrossRefGoogle Scholar
- 18.•Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867–77. This article includes all of the results from POSITRON and FUSION, phase III trials that treated patients with SOF who had chronic genotype 2 or 3 HCV infection and either could not receive interferon-based therapy or had poor responses to a previous course of interferon-based therapy.PubMedCrossRefGoogle Scholar
- 19.www.natap.org [homepage on the Internet]. Conference reports: 64rd [sic] Annual Meeting of the American Association for the Study of Liver Diseases Washington, DC Nov 1–5 2013. Reported by Jules Levin. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3; the VALENCE trial. National AIDS Treatment Advocacy Project; 2013 [cited Nov 4, 2013]. Available from: http://www.natap.org/2013/AASLD/AASLD_15.htm. Accessed 2 Jan 2014.
- 20.www.fda.gov [homepage on the Internet]. Birnkrant D, Mishra P, Florian J, Qi K. Presentations for the October 25, 2013 meeting of the Antiviral Drugs Advisory Committee: sofosbuvir NDA 204671 [slideset]. US Food and Drug Administration; 2013. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM375285.pdf. Accessed 11 Jan 2014.
- 21.www.fda.gov [homepage on the Internet]. FDA Antiviral Drugs Advisory Committee meeting background package for NDA 204671: sofosbuvir (GS-7977) Oct 25, 2013. US Food and Drug Administration; 2013.Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/antiviraldrugsadvisorycommittee/ucm371876.pdf. Accessed 11 Jan 2014.
- 22.www.fda.gov [homepage on the Internet]. Olysio (simeprevir) for the treatment of chronic hepatitis C in combination antiviral treatment. US Food and Drug Administration 2013 [updated 12/02/13, cited 1/11/14]. Available from: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm377234.htm. Accessed 11 Jan 2014.
- 23.www.fda.gov [homepage on the Internet]. FDA Antiviral Drugs Advisory Committee meeting background package for NDA 205123: simeprevir (TMC435) Oct 24, 2013. US Food and Drug Administration; 2013. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM371623.pdf. Accessed 11 Jan 2014.
- 24.www.fda.gov [homepage on the Internet]. Sherwat A. Presentations for the October 24, 2013 Antiviral Drugs Advisory Committee meeting: simeprevir (TMC435) [slideset]. US Food and Drug Administration 2013. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM375113.pdf. Accessed 11 Jan 2014.
- 27.Lawitz E, Forns X, Zeuzem S, et al. AGA abstracts: 869b. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: results from PROMISE, a phase III trial. AGA Abstracts. 2013;S–151.Google Scholar
- 28.Lenz O, Fevery B, Vijgen L, et al. TMC 435 in patients infected with HCV genotype 1 who have failed previous pegylated interferon/ribavirin treatment: virologic analysis of the ASPIRE trial. 47th Annual Meeting of the European Association for the Study of the Liver; 2012 April 18-22; Barcelona, Spain. Abstract 9.Google Scholar
- 29.www.fda.gov [homepage on the Internet]. Picchio G, Afdhal NH, Boven K, Beumont M, Lenz O, Jessner W. Janssen main presentations for the October 24, 2013 meeting of the Antiviral Drugs Advisory Committee: simeprevir (TMC435). [slideset] US Food and Drug Administration 2013. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM375115.pdf. Accessed 11 Jan 2014.
- 30.www.natap.gov [homepage on the Internet]. 64rd [sic] Annual Meeting of the American Association for the Study of Liver Diseases Washington, DC Nov 1-5, 2013. Reported by Jules Levin. SVR results of a once-daily regimen of simeprevir (SMV, TMC435) plus sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study. National AIDS Treatment Advocacy Project; 2013 [cited 11/05/13]. Available from: http://www.natap.org/2013/AASLD/AASLD_24.htm. Accessed 11 Jan 2014.
- 31.www.gilead.com [homepage on the Internet]. US Food and Drug Administration approves Gilead's Sovaldi™ (sofosbuvir) for the treatment of chronic hepatitis C. Dec 6, 2013. Available from: http://www.gilead.com/news/press-releases/2013/12/us-food-and-drug-administration-approves-gileads-sovaldi-sofosbuvir-for-the-treatment-of-chronic-hepatitis-c. Accessed 1 Feb 2014.
- 32.www.fairpricingcoalition.org [homepage on the Internet]. Fair Pricing Coalition disappointed by the high price of new Janssen hepatitis C drug Olysio (simeprevir). Nov 28, 2013. Available from: http://fairpricingcoalition.org/2013/11/28/fair-pricing-coalition-disappointed-by-the-high-price-of-new-janssen-hepatitis-c-drug-olysio-simeprevir/. Accessed 1 Feb 2014.